Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
Sponsor: Adaptimmune
ClinicalTrials ID:NCT03967223
This trial evaluates the safety and efficacy of letetresgene autoleucel in HLA-A*02+ participants with NY-ESO-1+ advanced synovial sarcoma or myxoid/round cell liposarcoma. Eligible participants must be ≥10 years old, weigh ≥40 kg, and have adequate organ function. Interventions include letetresgene autoleucel, fludarabine, and cyclophosphamide for lymphodepletion.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.
Description
New York esophageal antigen-1 (NY-ESO-1) and LAGE-1a antigens are tumor-associated proteins that have been found in several tumor types. Clinical trials using adoptively transferred T cells directed against NY-ESO-1/LAGE-1a have shown objective responses. Letetresgene autoleucel (lete-cel, GSK3377794) is the first generation of NY-ESO-1 specific T-cell receptor engineered T cells. This is a master protocol investigating T-cell therapies. It will initially consist of a core protocol with two independent substudies investigating Letetresgene autoleucel in previously untreated (1L) Human Leukocyte Antigen (HLA)-A*02+ participants with NY-ESO-1+ advanced (metastatic or unresectable) synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCLS) (Substudy 1) and Letetresgene autoleucel as second line or higher (2L+) treatment in HLA-A*02+ participants with NY-ESO-1+ advanced (metastatic or unresectable) SS or MRCLS who have progressed following treatment with anthracycline based chemotherapy (Substudy 2).
Eligibility Criteria
Inclusion Criteria
- Participant must be greater than or equal to 10 years of age on the day of signing informed consent.
- Participant scheduled to receive clinical drug product supply must also weigh ≥40 kg
- Participant must be positive for HLA-A*02:01, HLA-A*02:05, and/or HLA-A*02:06 alleles by a designated central laboratory
- Participant's tumor is positive for NY-ESO-1 expression by a designated central laboratory.
- Participant has a diagnosis of synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCLS)
- Performance status: dependent on age - Lansky > 60, Karnofsky > 60, Eastern Cooperative Oncology Group 0-1.
- Participant must have adequate organ function and blood cell counts, within 7 days prior to leukapheresis.
- At time of treatment, participant has measurable disease according to RECIST v1.1.
- Male or female. Contraception requirements will apply at the time of leukapheresis and treatment.
- Consultation for prior history per protocol specifications.
Exclusion Criteria
- Central nervous system metastases.
- Any other prior malignancy that is not in complete remission.
- Clinically significant systemic illness (Serious active infections or significant cardiac, pulmonary, hepatic or other organ dysfunction, that in the judgment of the Investigator would compromise the participant's ability to tolerate protocol therapy or significantly increase the risk of complications).
- Prior or active demyelinating disease.
- History of chronic or recurrent (within the last year prior to leukapheresis) severe autoimmune or immune mediated disease (e.g. Crohn's disease, systemic lupus) requiring steroids or other immunosuppressive treatments.
- Previous treatment with genetically engineered NY-ESO-1-specific T cells.
- Previous NY-ESO-1 vaccine or NY-ESO-1 targeting antibody.
- Prior gene therapy using an integrating vector.
- Previous allogeneic hematopoietic stem cell transplant.
- Washout periods for prior radiotherapy and systemic chemotherapy must be followed.
- Participant had major surgery in less than or equal to 28 days of first dose of study intervention.
- Prior radiation exceeds protocol specified limits.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| City of Hope National Medical Center | 91010 | Duarte | California |
| Stanford Hospital and Clinics | 94305 | Stanford | California |
| Sarah Cannon Research Institute | 80218 | Denver | Colorado |
| Mayo Clinic Jacksonville | 32224 | Jacksonville | Florida |
| University of Chicago | 60637 | Chicago | Illinois |
| University of Iowa College of Medicine | 52242-1009 | Iowa City | Iowa |
| Dana Farber Cancer Institute | 02114 | Boston | Massachusetts |
| Massachusetts General Hospital | 02114 | Boston | Massachusetts |
| University of Michigan Medical Center | 48109 | Ann Arbor | Michigan |
| Minnesota Oncology Hematology | 55455 | Minneapolis | Minnesota |
Get This Program In Your Inbox
You can sign up and apply your patients for this program.